Search
Descriptor English: Vindesine
Descriptor Spanish: Vindesina
Descriptor vindesina
Scope note: Derivado de la vinblastina con actividad antineoplásica en la leucemia aguda, el cáncer de pulmón, el carcinoma de la mama, el carcinoma de células escamosas del esófago, cabeza y cuello y linfomas de Hodgkin y no-Hodgkin. Sus principales efectos secundarios son la mielosupresión y la neurotoxicidad. La vindesina se utiliza ampliamente en protocolos de quimioterapia.
Descriptor Portuguese: Vindesina
Descriptor French: Vindésine
Entry term(s): Compound 112531
Desacetylvinblastine Amide
Eldisine
Enison
NSC 245467
NSC-245467
NSC245467
Sulfate, Vindesine
Vindesin
Vindesine Sulfate
Tree number(s): D03.132.436.681.827.830
D03.633.100.473.402.681.827.830
D03.633.100.496.500.500.681.827.830
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D014751
Scope note: Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antineoplastic Agents, Phytogenic
Tubulin Modulators
Registry Number: RSA8KO39WH
CAS Type 1 Name: Vincaleukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)-
Previous Indexing: Vinblastine/analogs & derivatives (1980-1985)
Vinca Alkaloids (1973-1979)
Public MeSH Note: 86
History Note: 86
DeCS ID: 19580
Unique ID: D014751
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1986/01/01
Date of Entry: 1985/04/24
Revision Date: 2017/05/24
Vindesine - Preferred
Concept UI M0022680
Scope note Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).
Preferred term Vindesine
Entry term(s) Desacetylvinblastine Amide
Vindesin
Eldisine - Narrower
Concept UI M0476562
Preferred term Eldisine
Entry term(s) Enison
Vindesine Sulfate - Narrower
Concept UI M0329487
Preferred term Vindesine Sulfate
Entry term(s) Sulfate, Vindesine
NSC-245467 - Narrower
Concept UI M0022682
Preferred term NSC-245467
Entry term(s) NSC 245467
NSC245467
Compound 112531 - Narrower
Concept UI M0353117
Preferred term Compound 112531



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey